The cardiovascular safety of oral alitretinoin: a population‐based cohort study involving 19 513 patients exposed to oral alitretinoin*-Reference-Cited by-同舟云学术

The cardiovascular safety of oral alitretinoin: a population‐based cohort study involving 19 513 patients exposed to oral alitretinoin*

Published:2021-05-25 Issue:4 Volume:185 Page:764-771
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Poizeau F.¹²³^ORCID,Balusson F.¹,Jonville‐Béra A.P.⁴⁵,Nowak E.²⁶⁷,Drici M.D.⁸,Scarabin P.Y.⁹,Droitcourt C.¹²³^ORCID,Dupuy A.¹²³,Oger E.¹²

Affiliation:

1. Univ Rennes CHU Rennes EA 7449 (Pharmacoepidemiology and Health Services Research) REPERES Rennes F 35043 France

2. PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety) Rennes France

3. Department of Dermatology CHU Rennes Rennes France

4. Centre Régional de Pharmacovigilance CHRU Tours Tours France

5. Université de Tours Université de Nantes INSERM – U 1246 France

6. University of Bretagne Occidentale Brest University Brest France

7. INSERM CIC 1412 CHRU Brest Brest France

8. Department of Clinical Pharmacology University of Cote d’Azur Medical Center Nice France

9. Centre de Recherche en Épidémiologie et Santé des Populations INSERM UMRS1018 Paris‐Saclay University Villejuif France

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.20069

Reference25 articles.

1. The epidemiology of hand eczema in the general population - prevalence and main findings

2. The association between atopic dermatitis and hand eczema: a systematic review and meta‐analysis

3. Incidence of Hand Eczema—A Population-Based Retrospective Study

4. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial

5. Efficacy and safety of oral alitretinoin as treatment for chronic hand eczema in france: a real‐life open‐label study;Halioua B;Eur J Dermatol,2019